Home
Storia in 1 fonti
VIDEO: Tucatinib extends PFS with no new safety signals in HER2-positive breast cancer
CHICAGO — In this video, Erika P. Hamilton, MD, discusses results from the HER2CLIMB-05 trial of tucatinib in combination with trastuzumab and pertuzumab as first-line maintenance therapy in HER2-positive metastatic breast cancer.The study, which compared tucatinib (Tukysa; Pfizer, Seagen) vs. placebo in combination with trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta,
Raccontata da
healio.com
Timeline cronologica
- ·
VIDEO: Tucatinib extends PFS with no new safety signals in HER2-positive breast cancer
CHICAGO — In this video, Erika P. Hamilton, MD, discusses results from the HER2CLIMB-05 trial of tucatinib in combination with trastuzumab and pertuzumab as first-line maintenance…
- ·
VIDEO: Sacituzumab govitecan delays subsequent therapy in breast cancer subset
CHICAGO — In this video, Sara A. Hurvitz, MD, FACP, discusses the ASCENT-03 study, which showed treatment with sacituzumab govitecan improved PFS and delayed subsequent therapy…